Physician profile
Jayasree Rao
NPI 1285662510
$12,811.81
in general payments reported to CMS, 2019-2025
74 companies · $25.70 in 2025
The $25.70 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,520 · 2020: $555 · 2021: $2,364 · 2022: $2,668 · 2023: $3,772 · 2024: $908 · 2025: $25.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,024 · Long Term Medical Supply Or Device Loan: $682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,023.66 |
| Long Term Medical Supply Or Device Loan | $681.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,735.22 | 2019-2024 | Kisqali, Piqray |
| Janssen Biotech, INC. | $992.20 | 2019-2023 | Darzalex, Erleada |
| E.R. Squibb & Sons, L.L.C. | $825.70 | 2019-2023 | Opdivo |
| Genzyme Corporation | $510.75 | 2019-2023 | |
| Genentech USA, INC. | $506.36 | 2019-2023 | Tecentriq, Lunsumio, Rituxan Hycela |
| Astrazeneca Pharmaceuticals LP | $504.04 | 2019-2024 | Enhertu, Calquence, Tagrisso |
| Celgene Corporation | $465.30 | 2021-2023 | Reblozyl, Pomalyst |
| Amgen INC. | $437.64 | 2019-2024 | Xgeva, Nplate, Vectibix |
| Eisai INC. | $398.00 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $377.45 | 2019-2023 | Keytruda, Lynparza |
| Puma Biotechnology, INC. | $319.59 | 2019-2023 | |
| Pfizer INC. | $279.17 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $262.63 | 2019-2023 | |
| Daiichi Sankyo INC. | $224.48 | 2019-2024 | Enhertu |
| Incyte Corporation | $208.57 | 2021-2023 | Jakafi |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $200.53 | 2019-2023 | Tukysa, Adcetris |
| Astellas Pharma US INC | $189.96 | 2019-2023 | Padcev, Xospata |
| Teva Pharmaceuticals USA, INC. | $186.97 | 2019-2021 | |
| Karyopharm Therapeutics INC. | $185.72 | 2020-2023 | Xpovio |
| Rigel Pharmaceuticals, INC. | $182.26 | 2019-2023 | Tavalisse, Rezlidhia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.72 | 2019-2023 | Gilotrif |
| Gilead Sciences, INC. | $155.93 | 2019-2023 | Trodelvy |
| Ipsen Biopharmaceuticals, INC | $147.95 | 2019-2023 | Onivyde, Somatuline Depot |
| Glaxosmithkline, LLC. | $147.04 | 2021-2023 | Shingrix, Ojjaara |
| Sobi, INC | $142.47 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $140.00 | 2019-2023 | Iclusig |
| Myriad Genetic Laboratories, INC. | $136.64 | 2023 | Precisetumor |
| Organon LLC | $135.85 | 2021-2023 | Ontruzant |
| Kite Pharma, INC. | $129.53 | 2021-2023 | Yescarta |
| Novo Nordisk INC | $124.99 | 2021 | |
| Array Biopharma INC | $118.05 | 2020-2023 | Mektovi, Lorbrena, Braftovi |
| Aveo Pharmaceuticals, INC. | $106.64 | 2021-2023 | Fotivda |
| Jazz Pharmaceuticals INC. | $105.39 | 2019-2023 | |
| Amneal Pharmaceuticals LLC | $103.10 | 2023-2024 | Avastin, Neupogen, Neulasta |
| Taiho Oncology, INC. | $99.69 | 2019-2023 | |
| Tersera Therapeutics LLC | $94.33 | 2022-2023 | Zoladex |
| Abbvie INC. | $92.38 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $90.50 | 2021-2023 | Libtayo |
| Emd Serono, INC. | $88.70 | 2019-2023 | Bavencio |
| Adc Therapeutics America, INC. | $76.91 | 2022-2023 | |
| Foundation Medicine, INC. | $74.25 | 2019-2022 | |
| Octapharma USA, INC. | $72.78 | 2023 | Panzyga, Octagam Immune Globulin (Human) |
| Pharmacosmos Therapeutics INC. | $72.12 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $68.98 | 2019-2023 | Ultomiris |
| Morphosys, US INC. | $68.93 | 2022-2023 | Monjuvi |
| Beigene USA, INC. | $68.40 | 2021-2023 | Brukinsa |
| Dova Pharmaceuticals | $67.91 | 2020-2021 | |
| Pharmaessentia USA Corporation | $66.44 | 2023 | Besremi |
| Lilly USA, LLC | $63.57 | 2019-2023 | Jaypirca, Retevmo |
| Servier Pharmaceuticals LLC | $60.71 | 2022-2025 | |
| Amag Pharmaceuticals, INC. | $56.58 | 2019-2021 | |
| Sandoz INC. | $54.39 | 2019 | |
| Cti Biopharma Corp. | $52.44 | 2022-2023 | Vonjo |
| Exelixis INC. | $43.36 | 2019-2023 | Cabometyx |
| Deciphera Pharmaceuticals INC. | $42.34 | 2021-2023 | Qinlock |
| Mylan Institutional INC. | $39.25 | 2019-2020 | |
| Adaptive Biotechnologies Corporation | $39.06 | 2021-2022 | |
| Kyowa Kirin, INC. | $37.92 | 2021-2022 | |
| Verastem, INC. | $37.51 | 2019 | |
| Janssen Pharmaceuticals, INC | $34.69 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $29.63 | 2021-2023 | Imbruvica |
| Sumitomo Pharma America, INC. | $25.24 | 2024 | Orgovyx |
| Sun Pharmaceutical Industries INC. | $23.98 | 2022 | |
| Apellis Pharmaceuticals, INC. | $23.00 | 2022 | |
| Tesaro, INC. | $22.30 | 2019 | |
| Tempus Ai, INC | $22.06 | 2024 | |
| Clovis Oncology, INC. | $20.79 | 2019 | |
| Agios Pharmaceuticals, INC. | $19.73 | 2023 | Pyrukynd |
| Helsinn Therapeutics (U.S.), INC. | $18.32 | 2019 | |
| Blueprint Medicines Corporation | $18.23 | 2023 | Ayvakit |
| Mirati Therapeutics, INC. | $16.91 | 2023 | Krazati |
| Tactile Systems Technology INC | $13.84 | 2021 | |
| Coherus Oncology, INC. | $13.68 | 2021 | |
| Epizyme, INC. | $13.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayasree Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.